Morgan Stanley has recently reduced Hims & Hers Health Inc (HIMS) stock rating, as announced on February 18, 2025, according to Finviz. Earlier, on January 10, 2025, Citigroup had reduced the stock from a Neutral to Sell, setting a price target of $25 for HIMS stock. BTIG Research also initiated Buy rating with a price target of $35. Additionally, Morgan Stanley initiated Overweight rating on December 17, 2024, with a target price of $42. BofA Securities analysts, in their report published on November 14, 2024, also reduced Underperform rating for Hims & Hers Health Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Hims & Hers Health Inc (HIMS) Stock Trading Recap
On Monday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $28.31 which represents a slight increase of $1.08 or 3.97% from the prior close of $27.23. The stock opened at $28.72 and touched a low of $27.2 during the day, reaching a high of $29. The volume of shares traded was 13.95 million falling short of the average volume of 24.29 million.
Sponsored
HIMS Stock Performance and Moving Averages
In recent trading, Hims & Hers Health Inc (HIMS) stock price has shown some volatility, fluctuating 1.94% over the last five trades and -14.57% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 58.60%, and it has gained 9.31% in the previous three months. Currently, HIMS is trading at -7.69%, -26.70%, and 7.19% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, HIMS, a Consumer Defensive sector stock, is trading -61.21% below its 52-week high but remains 152.77% above its 52-week low. The Average True Range (ATR) (14 days) of 3.79 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Hims & Hers Health Inc’s Profitability and Valuation Ratios
Hims & Hers Health Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 4.61% and a profit margin of 8.54%, with a gross margin of 58.60%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Hims & Hers Health Inc’s market capitalization stands at $6.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 52.94, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 32.02. Additionally, the Price-to-Sales Ratio is 4.26, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 13.11, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 18.10% of Hims & Hers Health Inc (HIMS)’s shares, while financial institutions hold 73.83%.
Notable insider trades include Baird Melissa, Chief Operating Officer at Hims & Hers Health Inc (HIMS), who sold 33,337 shares on Apr 09 ’25, at $27.32 each, totaling $0.91 million. On Apr 02 ’25, Okupe Oluyemi, Chief Financial Officer, sold 11,581 shares for $29.26 each, amounting to $0.34 million. Additionally, on Mar 26 ’25, Baird Melissa sold 67,687 shares at $34.84 each, generating $2.36 million.
